Ponesimod vs Tascenso ODT

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline

Ponesimod

Marketed by Vanda Pharmaceuticals and partners

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT02425644 · Phase 3 · completed

This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.

Reported efficacy

Annualized Confirmed Relapse Rate (From randomization to end of study (Week 108)): Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. (met)

Result source: NCT02425644

Tascenso ODT

Marketed by Cycle Pharmaceuticals Ltd. and partners

Approved in Multiple Sclerosissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPonesimodTascenso ODT
Annualised relapse rate0.2 vs 0.3vs Teriflunomide20 mg · wk 108 · n 567NCT02425644—Not reported
Free of 3-month confirmed disability progression (%)—Not reported—Not reported
New or enlarging T2 lesions—Not reported—Not reported

Annualised relapse rate

Ponesimod
0.2 vs 0.3vs Teriflunomide20 mg · wk 108 · n 567NCT02425644
Tascenso ODT
—Not reported

Free of 3-month confirmed disability progression (%)

Ponesimod
—Not reported
Tascenso ODT
—Not reported

New or enlarging T2 lesions

Ponesimod
—Not reported
Tascenso ODT
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Tascenso ODT: no structured comparison results are available for Multiple Sclerosis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ponesimod: 4 of 4 rows · Tascenso ODT: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPonesimod
Dropout rate
13.6%20 mga
NCT02425644 · Phase 3
show 4 more results
19.8%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
33.9%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
35%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
38.3%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.3%20 mga
NCT02425644 · Phase 3
show 4 more results
1.6%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
0.8%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
3.4%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
1.7%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Serious AEs
8.7%20 mga
NCT02425644 · Phase 3
show 4 more results
12.8%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
24.1%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
16.6%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
23%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
20 mga
alanine aminotransferase increased 19.5%
nasopharyngitis 19.3%
headache 11.3%
NCT02425644 · Phase 3
show 4 more results
20 mg
covid-19 26.2%
nasopharyngitis 18.7%
alanine aminotransferase increased 16.6%
NCT03232073 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 31.7%
headache 21.4%
upper respiratory tract infection 19.3%
NCT01093326 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 29.8%
headache 27.2%
upper respiratory tract infection 25.8%
NCT01093326 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 33.1%
headache 27.3%
upper respiratory tract infection 19.4%
NCT01093326 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ponesimod

Annualized Relapse 0.202 vs 0.29 Teriflunomide per year @ 108wk20 mg
event rate · per year
NCT02425644 · Phase 3
FSIQ-RMS Symptoms Domain -0.01 vs 3.56 Teriflunomide score @ 108wk20 mg
absolute change · score
NCT02425644 · Phase 3
CUAL Rate Annualized 1.405 vs 3.164 Teriflunomide per year @ 108wk20 mg
event rate · per year
NCT02425644 · Phase 3
Confirmed Disability Progression 12w 7.6% (n=567) vs 8.3% (n=566) Teriflunomide @ 60wk20 mg
responder rate · % of participants
NCT02425644 · Phase 3
show 1 more result
10.8% (n=567) vs 13.2% (n=566) Teriflunomide @ 108wk20 mg
NCT02425644 · Phase 3
Confirmed Disability Progression 24w 6.3% (n=567) vs 6.9% (n=566) Teriflunomide @ 60wk20 mg
responder rate · % of participants
NCT02425644 · Phase 3
show 1 more result
8.7% (n=567) vs 10.5% (n=566) Teriflunomide @ 108wk20 mg
NCT02425644 · Phase 3
Annualized Relapse 0.143 vs 0.184 Teriflunomide then Ponesimod per year20 mg
event rate · per year
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to First Relapse 92.93 vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence · converted to months from 402.71 weeks as posted
Time to 3m Confirmed Disability Worsening NA vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to CDP 6mo NA vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Relapse Free 56.7% (n=439) vs 51.6% (n=438) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
EDSS 0.16 vs 0.34 Teriflunomide then Ponesimod score20 mg
absolute change · score
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
NEDA 17.5% (n=439) vs 7.5% (n=436) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence

+ 11 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ponesimod's landscape · Tascenso ODT's landscape